Measuring breast, colorectal, and prostate cancer screening with medicare claims data.

Jean L. Freeman, Carrie N. Klabunde, Nicola Schussler, Joan L. Warren, Beth A. Virnig, Gregory S. Cooper

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

BACKGROUND: Evaluating the use and effectiveness of cancer screening is an important component of cancer control programs. Medicare claims may be a useful source of data when screening older populations, but they are limited in terms of completeness and the ability to distinguish screening tests from those provided for diagnosis or surveillance. RESEARCH DESIGN: A review of the major screening modalities for breast, colorectal, and prostate cancer, Medicare's policies for covering these tests, and the procedure codes used to identify them in Medicare claims. RESULTS: Although Medicare's coverage has been extended to include screening mammography, colonoscopy, sigmoidoscopy, fecal occult blood tests, double-contrast barium enema, and prostate-specific antigen tests, providers have been slow to adopt the corresponding screening codes. CONCLUSION: Challenges persist in measuring screening use, and innovative approaches are required to distinguish screening tests from diagnostic and follow-up evaluations.

Original languageEnglish (US)
JournalMedical Care
Volume40
Issue number8 Suppl
StatePublished - Aug 2002

Fingerprint

Medicare
Early Detection of Cancer
Colorectal Neoplasms
Prostatic Neoplasms
cancer
Breast Neoplasms
Sigmoidoscopy
Occult Blood
Information Storage and Retrieval
Hematologic Tests
Mammography
Colonoscopy
Prostate-Specific Antigen
Routine Diagnostic Tests
surveillance
diagnostic
coverage
Population
ability
Neoplasms

ASJC Scopus subject areas

  • Nursing(all)
  • Public Health, Environmental and Occupational Health
  • Health(social science)
  • Health Professions(all)

Cite this

Freeman, J. L., Klabunde, C. N., Schussler, N., Warren, J. L., Virnig, B. A., & Cooper, G. S. (2002). Measuring breast, colorectal, and prostate cancer screening with medicare claims data. Medical Care, 40(8 Suppl).

Measuring breast, colorectal, and prostate cancer screening with medicare claims data. / Freeman, Jean L.; Klabunde, Carrie N.; Schussler, Nicola; Warren, Joan L.; Virnig, Beth A.; Cooper, Gregory S.

In: Medical Care, Vol. 40, No. 8 Suppl, 08.2002.

Research output: Contribution to journalArticle

Freeman, JL, Klabunde, CN, Schussler, N, Warren, JL, Virnig, BA & Cooper, GS 2002, 'Measuring breast, colorectal, and prostate cancer screening with medicare claims data.', Medical Care, vol. 40, no. 8 Suppl.
Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring breast, colorectal, and prostate cancer screening with medicare claims data. Medical Care. 2002 Aug;40(8 Suppl).
Freeman, Jean L. ; Klabunde, Carrie N. ; Schussler, Nicola ; Warren, Joan L. ; Virnig, Beth A. ; Cooper, Gregory S. / Measuring breast, colorectal, and prostate cancer screening with medicare claims data. In: Medical Care. 2002 ; Vol. 40, No. 8 Suppl.
@article{54490dd075074c229ba67012d9f3fea1,
title = "Measuring breast, colorectal, and prostate cancer screening with medicare claims data.",
abstract = "BACKGROUND: Evaluating the use and effectiveness of cancer screening is an important component of cancer control programs. Medicare claims may be a useful source of data when screening older populations, but they are limited in terms of completeness and the ability to distinguish screening tests from those provided for diagnosis or surveillance. RESEARCH DESIGN: A review of the major screening modalities for breast, colorectal, and prostate cancer, Medicare's policies for covering these tests, and the procedure codes used to identify them in Medicare claims. RESULTS: Although Medicare's coverage has been extended to include screening mammography, colonoscopy, sigmoidoscopy, fecal occult blood tests, double-contrast barium enema, and prostate-specific antigen tests, providers have been slow to adopt the corresponding screening codes. CONCLUSION: Challenges persist in measuring screening use, and innovative approaches are required to distinguish screening tests from diagnostic and follow-up evaluations.",
author = "Freeman, {Jean L.} and Klabunde, {Carrie N.} and Nicola Schussler and Warren, {Joan L.} and Virnig, {Beth A.} and Cooper, {Gregory S.}",
year = "2002",
month = "8",
language = "English (US)",
volume = "40",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "8 Suppl",

}

TY - JOUR

T1 - Measuring breast, colorectal, and prostate cancer screening with medicare claims data.

AU - Freeman, Jean L.

AU - Klabunde, Carrie N.

AU - Schussler, Nicola

AU - Warren, Joan L.

AU - Virnig, Beth A.

AU - Cooper, Gregory S.

PY - 2002/8

Y1 - 2002/8

N2 - BACKGROUND: Evaluating the use and effectiveness of cancer screening is an important component of cancer control programs. Medicare claims may be a useful source of data when screening older populations, but they are limited in terms of completeness and the ability to distinguish screening tests from those provided for diagnosis or surveillance. RESEARCH DESIGN: A review of the major screening modalities for breast, colorectal, and prostate cancer, Medicare's policies for covering these tests, and the procedure codes used to identify them in Medicare claims. RESULTS: Although Medicare's coverage has been extended to include screening mammography, colonoscopy, sigmoidoscopy, fecal occult blood tests, double-contrast barium enema, and prostate-specific antigen tests, providers have been slow to adopt the corresponding screening codes. CONCLUSION: Challenges persist in measuring screening use, and innovative approaches are required to distinguish screening tests from diagnostic and follow-up evaluations.

AB - BACKGROUND: Evaluating the use and effectiveness of cancer screening is an important component of cancer control programs. Medicare claims may be a useful source of data when screening older populations, but they are limited in terms of completeness and the ability to distinguish screening tests from those provided for diagnosis or surveillance. RESEARCH DESIGN: A review of the major screening modalities for breast, colorectal, and prostate cancer, Medicare's policies for covering these tests, and the procedure codes used to identify them in Medicare claims. RESULTS: Although Medicare's coverage has been extended to include screening mammography, colonoscopy, sigmoidoscopy, fecal occult blood tests, double-contrast barium enema, and prostate-specific antigen tests, providers have been slow to adopt the corresponding screening codes. CONCLUSION: Challenges persist in measuring screening use, and innovative approaches are required to distinguish screening tests from diagnostic and follow-up evaluations.

UR - http://www.scopus.com/inward/record.url?scp=17144462668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144462668&partnerID=8YFLogxK

M3 - Article

C2 - 12187166

AN - SCOPUS:17144462668

VL - 40

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 8 Suppl

ER -